On International Women’s Day, we celebrate all women in science and health. The OraSure family of companies, including Diversigen, DNA Genotek, and Novosanis, are proud to include a diverse...
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM...
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine.
Novosanis is offering a research grant in collaboration with EACR to stimulate innovative research in cancer biomarker detection using urine as a sample type. Urine can be collected in an...
Novosanis hosted a virtual booth at Eurogin 2021, an international conference focusing on Human Papillomavirus (HPV). Urine, particularly, first-void urine, has potential to screen for...
It is well-established that Human Papillomavirus (HPV), the primary cause of cervical cancer can be detected in first-void urine. The study by Laura Téblick (University of Antwerp, Belgium...
We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp.
What a milestone! 8 years and counting. To celebrate our 8th anniversary, we asked our team members to describe Novosanis and their experience in unique words. Teamwork and Innovation were...
In view of the spread of Covid-19 (coronavirus) in our country and across the world, our topmost priority is the health and safety of all our customers and employees. Our team will be...
Novosanis
